ANCA相关性血管炎患者的死亡风险:观察性研究的荟萃分析
该荟萃分析纳入10项观察性研究、共3338例ANCA相关性血管炎(AAV)患者,汇总显示AAV患者全因死亡风险约为一般人群的2.7倍(meta-SMR 2.71,95%CI 2.26–3.24)。仅纳入肉芽肿性多血管炎的研究亦显示相似风险(meta-SMR 2.63,95%CI 2.02–3.43),且死亡风险在较老队列中更高、随时间呈改善趋势。
要点
- AAV患者全因死亡风险约为一般人群的2.7倍。
- 仅肉芽肿性多血管炎患者死亡风险相似,meta-SMR为2.63。
- 较老队列死亡风险更高,随时间呈改善趋势。
核心结论
- 已发表数据表明AAV患者死亡风险较一般人群增加2.7倍。
研究设计与样本
- 检索Medline和Embase自建库至2015年4月的观察性研究,由两名研究者评估纳入。
- 纳入标准为AAV诊断明确(1990年ACR分类标准或2012年Chapel Hill共识会议定义)且报告SMR及95%CI。
- 共纳入10项研究,含3338例AAV患者(入组时间1966至2009年),观察死亡1091例。
- 采用随机效应模型计算全因死亡SMR的加权汇总估计,并检验发表偏倚与异质性。
主要发现
- 总体meta-SMR为2.71(95%CI 2.26–3.24),即AAV患者死亡风险为一般人群的2.7倍。
- 仅纳入肉芽肿性多血管炎病例的研究meta-SMR为2.63(95%CI 2.02–3.43)。
- 未发现显著发表偏倚或小样本效应。
- 亚组分析显示较老队列死亡风险更高,随时间呈改善趋势(入组期中点1980–1993与1994–1999对比2000–2005)。
关键数值与推荐
- AAV诊断依据1990年ACR分类标准或2012年Chapel Hill共识会议疾病定义。
- 纳入研究需报告SMR及95%CI。
- 总体meta-SMR为2.71(95%CI 2.26–3.24)。
- 肉芽肿性多血管炎亚组meta-SMR为2.63(95%CI 2.02–3.43)。
临床怎么用
- 临床应认识到AAV患者全因死亡风险显著高于一般人群,需加强长期随访与共病管理。
- 较老队列死亡风险更高、随时间改善的趋势提示诊疗进步可能改善预后。
局限性
- 仅纳入报告SMR及95%CI的观察性研究,可能存在选择偏倚。
- 原文未报告纳入研究间的异质性具体数值。
- 原文未报告各研究的详细特征及混杂因素控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the magnitude of all-cause mortality risk in patients with antineutrophil cytoplasmic antibodies-associated vasculitis (AAV) compared with the general population through a meta-analysis of observational studies. METHODS: We searched Medline and Embase databases from their inception to April 2015. Observational studies that met the following criteria were assessed by two researchers: (1) clearly defined AAV identified by either the American College of Rheumatology 1990 classification criteria or the 2012 Chapel Hill Consensus Conference disease definitions, and (2) reported standardised mortality ratios (SMR) and 95% CI. We calculated weighted-pooled summary estimates of SMRs (meta-SMRs) for all-cause mortality using random-effects model, tested for publication bias and heterogeneity. RESULTS: Ten studies met the inclusion criteria, comprising 3338 patients with AAV enrolled from 1966 to 2009, and a total of 1091 observed deaths. Overall, we found a 2.7-fold increased risk of death in patients with AAV when compared with the general population (meta-SMR: 2.71 (95% CI 2.26 to 3.24)). Analysis on studies that included only granulomatosis with polyangiitis cases also indicated a similar mortality risk (meta-SMR: 2.63 (95% CI 2.02 to 3.43)). There was no significant publication bias or small-study effect. Subgroup analyses showed that mortality risks were higher in older cohorts, with a trend towards improvement over time (ie, those with their midpoint of enrolment periods that were between 1980-1993 and 1994-1999, vs 2000-2005). CONCLUSION: Published data indicate there is a 2.7-fold increase in mortality among patients with AAV compared with the general population.
引用
- Tan JA, Dehghan N, Chen W, et al. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. Ann Rheum Dis. 2017. PMID: 28468793. doi:10.1136/annrheumdis-2016-210942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。